Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of SYNB1934 in Healthy Volunteers
NCT04984525Phase 1Completed
- Sponsor
- Synlogic
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of labafenogene marselecobac in phenylketonuria (PKU) (6 arms), sponsored by Synlogic. Primary endpoint: Number of Subjects With Treatment-Emergent Adverse Events at 70 days. Started Jul 2021; status: completed.
02
Drugs
labafenogene marselecobac
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT04984525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984525.